Back to results
US 11,324,836 B2Granted
Modified virus-like particles of CMV
AssigneeSaiba GmbH
InventorsMartin Bachmann, Andris Zeltins, Paul Pumpens
Life of this patent
Estimating the term…
Abstract
The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.
Claims20
A composition comprising:
- (a) a modified virus-like particle (VLP) of cucumber mosaic virus (CMV), wherein said modified VLP of CMV comprises at least one modified CMV polypeptide, wherein said modified CMV polypeptide comprises
- i. a CMV polypeptide, wherein said CMV polypeptide comprises
- (x) an amino acid sequence of a coat protein of CMV;
- or
- (y) mutated amino acid sequence, wherein the amino acid sequence to be mutated is an amino acid sequence of a coat protein of CMV, and wherein said mutated amino acid sequence and said coat protein of CMV show a sequence identity of at least 90%;
- and
- ii. a T helper cell epitope;
- wherein said T helper cell epitope replaces a N-terminal region of said CMV polypeptide, wherein said N-terminal region of said CMV polypeptide corresponds to amino acids 2-12 of SEQ ID NO:1;
- and wherein said modified virus-like particle comprises at least one first attachment site;
- and
- (b) at least one antigen, wherein said antigen comprises at least one second attachment site;
- and
- wherein said antigen is selected from
- a) IL-17;
- b) IL-17, wherein said antigen comprises SEQ ID NO:42;
- c) human IL-5 and canine IL-5;
- d) IL-5, wherein said antigen comprises SEQ ID NO:41;
- e) TNFα;
- f) IL-1α;
- g) IL-13
- h) IL-13, wherein said antigen comprises SEQ ID NO:46;
- i) a peptide derived from Aβ1-42;
- j) IgE or a peptide or domain comprised in IgE;
- k) α-synuclein or a peptide derived from α-synuclein
- l) α-synuclein or a peptide derived from α-synuclein, wherein said peptide consists of 6 to 14 amino acids, and wherein said antigen is a peptide derived from α-synuclein selected from any one of SEQ D NO:32, SEQ ID NO:33 and SEQ ID NO:34;
- m) IL-4
- n) IL-4, wherein said antigen comprises SEQ ID NO:45;
- o) GnRH;
- p) the extracellular domain of Influenza A virus M2 protein, or an antigenic fragment thereof;
- q) human IL-31, canine IL-31 and feline IL-31;
- r) human IL-31, wherein said antigen comprises SEQ ID NO:43;
- s) canine IL-31, wherein said antigen comprises SEQ ID NO:44
- t) an antigen derived from Plasmodium falciparum or Plasmodium Vivax, or wherein said antigen is the derived from RSV;
- u) IL-1β;
- v) IL-1β, wherein said antigen comprises SEQ ID NO:60;
- w) the dog allergen Can f1 or Can f2;
- x) calcitonin gene-related peptide (CGRP);
- and
- y) Amylin;
- wherein (a) and (b) are linked through said at least one first and said at least one second attachment site.
37 more elements
Dependencies are inferred from the claim text.